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study
Meier Rahel, Keizer Ellen, Rosemann Thomas, Markun Stefan
Institute of Primary Care, University of Zurich and University Hospital Zurich, Switzerland
Summary
BACKGROUND: Intravenous iron supplementation (IVIS)
is increasing in Swiss general practice. This is controver-
sial because of higher costs and risks compared with oral
iron supplementation (OIS). In this study, we aimed to in-
vestigate indications for OIS and IVIS in Swiss general
practice and test which factors are associated with pre-
scribing IVIS instead of OIS.
METHODS: This was a retrospective observational study
using data from electronic medical records of 279 Swiss
general practitioners (GPs), including all their patients at
their first OIS and IVIS administration who were at least
14 years old and with available pretreatment serum ferritin
and haemoglobin measurements. We also collected data
about the following comorbidities: chronic kidney disease
(CKD) stage 3b or higher, inflammatory bowel disease
(IBD), chronic heart failure and restless legs syndrome.
Outcomes were proportions of cases treated with IVIS or
OIS by assumed indication (anaemic or non-anaemic iron
deficiency [NAID]) or the abovementioned comorbidities.
We evaluated associations with IVIS prescription using re-
gression models adjusting for patient and GP variables.
RESULTS: We assessed 1282 IVIS and 3003 OIS cases
(median age 44 and 40 years, female in 86.7 and 88.6%,
respectively). The most important indication for both IVIS
and OIS was NAID (59.4 and 74.7%, respectively). Sig-
nificant associations with prescribing IVIS instead of OIS
were the severity of iron deficiency (reflected by serum fer-
ritin levels and the presence of anaemia), the presence of
advanced CKD, IBD and male sex of the GP. There was a
time trend towards increasing serum ferritin levels associ-
ated with initiation of IVIS in NAID.
CONCLUSION: When preferring IVIS to OIS, Swiss GPs
seem to consider severity of iron deficiency and comorbid
conditions. However, pretreatment serum ferritin levels in
IVIS for NAID are increasing, suggesting an ongoing indi-
cation extension and potential overuse.
Keywords: general practice, overuse, iron supplementa-
tion, non-anaemic iron deficiency
Introduction
Iron deficiency is the leading cause of anaemia in central
European countries, the most common cause being men-
strual blood loss in women [1]. Iron deficiency can be
diagnosed on the basis of serum ferritin levels before
anaemia occurs [2]. However, target values for serum fer-
ritin vary, as patient populations have been identified that
benefit from significantly increased iron storage, namely
patients with chronic kidney disease (CKD) [3, 4], chronic
heart failure (CHF) [5] and restless legs syndrome (RLS)
[6]. Evidence suggests that non-anaemic iron deficiency
(NAID) may play a role in otherwise unexplained fatigue,
further extending the spectrum of potential indications for
iron supplementation beyond iron deficiency anaemia
[7–9].
Iron supplementation may be administered orally or intra-
venously. Oral iron supplementation (OIS) is the recom-
mended first-line treatment because of lower direct costs
and fewer safety concerns, and intravenous iron supple-
mentation (IVIS) is recommended as second-line treatment
after OIS has proven ineffective [10, 11]. In specific pa-
tient populations, IVIS is a recognised first-line treatment,
namely when intestinal iron absorption is impaired as in in-
flammatory bowel disease (IBD) [12] or when serum fer-
ritin concentrations above 100 ng/ml are targeted, such as
in CKD [13], CHF [14] or RLS [6].
In recent years, IVIS prescriptions have increased in
Switzerland: Analysing data from insurance claims, Giger
et al. found that IVIS prescription increased by 250% be-
tween 2006 and 2010 [15]. Also according to claims data,
Bietry et al. found that IVIS prescription rates are a stag-
gering thousand times higher in Switzerland than in the
United Kingdom [16]. So far, it is unclear what causes this
increase in IVIS prescriptions and several reasons seem
plausible. One could be the increasing recognition of
NAID [8, 9], based on the extension of the serum ferritin
threshold defining iron deficiency above the value of 15
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ng/ml proposed by the World Health Organization (WHO)
[17, 18]. However, it is also possible that patients receiving
IVIS are diagnosed with specific conditions proven to ben-
efit from IVIS. Unfortunately, previous studies describing
the increase in IVIS were based on claims data only and
thus they were unable to investigate questions about the
clinical circumstances under which iron supplementation
was initiated.
Therefore, the aim of this study was to investigate indica-
tions for OIS and IVIS in Swiss general practice and test
which factors are associated with prescribing IVIS instead
of OIS.
Methods
Study design and setting
This study was a retrospective observational database
analysis of Swiss general practice using data from the
FIRE (Family Medicine ICPC-Research using Electronic
Medical Records) project [19]. The FIRE project is a net-
work of Swiss general practitioners (GPs) who export
anonymised routine data from their electronic medical
records (EMR); participation is free of charge and volun-
tary. The GPs contribute to a central database the follow-
ing data: administrative data, laboratory values, medication
data, vital signs and, if available, International Classifica-
tion of Primary Care (ICPC) diagnoses. Since the project
started in 2009, 441 GPs (8.6% of GPs working in the
German-speaking region of Switzerland [20]) have joined
the network, bringing with them over 518,000 patients and
more than four million consultations. We assessed all data
from the observation period included in the FIRE database
(search range from January 2009 to August 2018).
Participants
All GPs in the FIRE network using EMR with interfaces
exporting serum ferritin laboratory analyses (observation
starting from the first exported serum ferritin value) were
eligible.
Patient inclusion criterion was receiving any pure iron sup-
plementation (OIS or IVIS, anatomical therapeutic chem-
ical classification [ATC] codes [21]: B03AA, B03AB and
B03AC) during the full observation period. If several iron
supplements of the same kind (multiple treatment cycles)
were issued to the same patient, only the first of each kind
(OIS or IVIS) was included in order to prevent over-rep-
resentation of individual patients. Patient were excluded
if: (a) the initiation date of iron supplementation coincided
with the date of first record in the FIRE database (because
iron supplementation may have been ongoing in some of
these patients and the encounter in question just be a fol-
low-up, and not the true initiation of iron supplementa-
tion); (b) treatment was before age of 14 years. In cases
meeting the inclusion criterion, we assessed whether serum
ferritin and haemoglobin measurements were available to
allow determination of anaemia and iron status. Cases with
available measurements were included for further analysis.
The GP, patient and case selection process is visualised in
the study flowchart (see fig. 1 below).
Database query, variables and diagnostic criteria
From the included cases, we retrieved: (a) demographic da-
ta (age, sex and body mass index (BMI)); (b) treatment da-
ta (prescription date, treatment modality OIS or IVIS); (c)
laboratory data (results of serum ferritin and haemoglobin
measurements within 90 days preceding iron prescription,
coding anaemia in female cases with haemoglobin <12 g/
dl and male cases <13 g/dl) [22]; and (d) presence of con-
current conditions relevant to iron prescribing. We identi-
fied CKD stage 3b or higher, IBD, CHF and RLS by ei-
ther considering diagnostic ICPC coding, prescribed drugs
with high disease specificity or laboratory values with high
specificity (CKD stage 3b or higher: at least two previ-
ous creatinine measures indicating an impaired glomeru-
lar filtration rate of <90 ml/min and at least one measure-
ment <45 ml/min; IBD: ICPC code D94 or ATC codes
A07EA06, A07EC01, A07EC02, A07FA; CHF: ICPC
code K77; RLS: ICPC code N04). Cases without concur-
rent conditions were classified as iron deficiency anaemia
(IDA) if anaemic and NAID if not anaemic.
Outcomes
Outcomes of the study were as follows:
Proportions of cases by assumed indication for iron sup-
plementation (IDA, NAID or presence of at least one spe-
cific comorbidity of either CKD, CHF or RLS). Cases with
NAID were further subdivided into proportions of cases
falling within predefined serum ferritin bands of <15 ng/
ml, 15–29 ng/ml or ≥30ng/ml. Cases with IBD were in-
cluded in the IDA or NAID group because the primary in-
dication for these patients is not the IBD itself but the iron
deficiency.
Associations of patient and GP characteristics with treat-
ment modality (IVIS or OIS).
Time trends in serum ferritin levels associated with iron
supplementation in NAID.
Ethical approval
According to the Local Ethics Committee of the Canton of
Zurich, the project does not fall under the scope of the law
on human research and therefore no ethical consent is nec-
essary (BASEC-Nr. Req-2017-00797).
Data analysis
We described categorical data as counts and proportions
(n, %) and numerical data as mean and standard deviation
(SD) or median and interquartile range (IQR), as appro-
priate. For group comparisons, we used the Wilcoxon rank
sum test, Welch two-sample t-test, χ2-test or Fisher’s exact
test, as appropriate. To assess associations with treatment
modality (IVIS or OIS), we used a generalised mixed mod-
el: the dependent variable was treatment modality; inde-
pendent variables were patient characteristics (sex and
age), year of treatment, comorbidities (IBD, CKD, CHF),
severity of iron deficiency (anaemia and serum ferritin)
and GP variables (sex and age), adjusting for GP identity
as nested variable within the GP practice. We reported
odds ratios (ORs) and 95% confidence intervals (CIs) for
each factor included in the model.
To assess whether pretreatment serum ferritin levels in
NAID changed over time we used graphical representation
and a linear mixed model with serum ferritin as dependent
Original article Swiss Med Wkly. 2019;149:w20127
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 2 of 9
variable. The independent variable was treatment modality.
We adjusted for patient characteristics (sex and age), GP
variables (sex and age) and GP identity as nested variable
within the GP practice. We reported change over time as
percentage increase per year. The p-value was set at ≤ 0.05.
R (Version 3.5.0) was used for statistical analysis [23].
Results
Population
Data interfaces from 116 practices in the FIRE network ex-
ported serum ferritin measurements and were therefore el-
igible for this study. GPs (n = 279) in the dataset had a me-
dian age of 51 years (IQR 43–60); 61.4% were male and
83.0% were working in group practices. GPs’ median time
under observation was 487 days (IQR 240–1017). A total
of 10,912 patients met the inclusion criterion of starting
OIS or IVIS; however, 2512 of these met at least one of the
exclusion criteria at the patient level. On the level of cases,
4285 (OIS 3003 and IVIS 1282) met the inclusion criterion
of available haemoglobin and serum ferritin measurements
within 90 days preceding initiation of iron supplementation
and thus composed the final dataset for subsequent analy-
ses (fig. 1). Per individual GP, there was a median of 6 OIS
cases (IQR 2–13, range 0–137) in the dataset and a median
of 3 IVIS cases (IQR 1–9, range 0–57).
Compared with OIS cases, IVIS cases were associated
with significantly older age, lower serum ferritin and lower
haemoglobin levels (table 1). Higher proportions of IBD
and CKD stage 3b or higher were associated with IVIS. Of
the 1282 IVIS cases, 240 (18.7%) had previously received
OIS (median interval between OIS and IVIS 102 days, IQR
31–212).
Indications for OIS and IVIS
The majority of cases for both OIS and IVIS were treated
without having anaemia, CKD, CHF or RLS and thus fell
into the NAID indication group. Indications differed sub-
stantially between OIS and IVIS: NAID 74.7 vs 59.4%;
IDA 23.0 vs 34.9% and either CKD, CHF or IBD 2.3
vs 5.6%, respectively (see fig. 1 for comparative classifi-
cation flow). Most NAID cases fell into the category of
serum ferritin between 15 and 29 ng/ml, regardless of treat-
ment modality.
Associations with treatment modality
We found that the strongest association for initiating IVIS
instead of OIS was serum ferritin <15 ng/ml (OR 3.7, 95%
CI 2.6–5.0, ref. serum ferritin ≥30 ng/ml). Other strong as-
sociations with IVIS initiation were serum ferritin 15 to 29
ng/ml (OR 2.2, 95% CI 1.7–2.7, ref. serum ferritin ≥30 ng/
ml), chronic kidney disease stage 3b or higher (OR 2.0,
95% CI 1.2–3.4), anaemia (OR 2.0, 95% CI 1.6–2.5) and
the GP being male (OR 1.8, 95% CI 1.1–2.9). We found a
weak association for IBD (OR 1.4, 95% CI 1–1.9). See fig-
ure 2 for visualisation of associations with prescription of
IVIS instead of OIS.
Multilevel adjustment for GPs nested in GP practices
showed that there was a significant association on the level
of GP practices with prescribing IVIS instead of OIS, but
not on the level of individual GPs (see supplementary fig.
S1 in appendix 1)
Time trend exploration
Graphical representation showed a trend towards increas-
ing pretreatment serum ferritin thresholds with IVIS for
NAID but not with OIS (fig. 3). The linear regression mod-
el confirmed the trend towards increase of serum ferritin
levels; however, the trend was statistically not significant
(yearly increase of serum ferritin in IVIS 3.0%; p = 0.096).
Discussion
This study showed that GPs used iron supplementation
mainly in NAID and in most of these cases serum ferritin
levels were above the threshold of 15 ng/ml recommended
by the WHO [17] and renowned experts [11, 24]. This
finding suggests an indication extension in Swiss general
practice towards treatment for higher serum ferritin values
and raises concerns about potential overtreatment. GPs’
decisions to use IVIS instead of OIS were associated with
patient characteristics such as severity of iron deficiency
and comorbidities, but also with GP characteristics, name-
ly GPs’ sex and the GP practice. Serum ferritin levels prior
to IVIS for NAID varied widely and seemed to rise over
time, indicating a liberalisation of IVIS initiation.
Research in context
Previous studies have described prescription rates and
costs of IVIS in Swiss outpatient care. Between 2006 and
2010, IVIS prescriptions increased by 244% and related
costs increased by 340% (EUR 16.5 Mio) [15]. Between
2012 and 2014 prescription rates continued to increase
and IVIS prescription rates became a thousand times high-
er in Switzerland than in the UK, according to Biétry et
al. [16]. These studies, however, provided no information
on indications and laboratory values associated with iron
supplementation, which we investigated in our study. We
found that one in 18 cases receiving IVIS belonged to a
population with comorbidities primarily demanding intra-
venous treatment and serum ferritin targets of 100 ng/ml
or higher (CHF, CKD). Only one in three cases of IVIS
had haemoglobin values in the anaemic range. Moreover,
at least every second case had neither a comorbid disease
demanding IVIS nor anaemia, thus falling under the defi-
nition of NAID (fig. 1). Treatment of NAID with IVIS is
most controversial because there is no evidence suggesting
favourable effects on objective measures and only mod-
erate evidence for fatigue, as a recent systematic review
showed [25]. Fatigue is presumably among the most com-
mon reasons for treating NAID in general practice. No-
tably, the abovementioned systematic review found only
two randomised controlled trials testing IVIS [26, 27]. One
of these trials showed no effectiveness in the total study
population, but the subgroup of individuals with serum fer-
ritin levels <15 ng/ml seemed to benefit [27]. The other tri-
al showed effectiveness, but had a serum ferritin level <15
ng/ml among its inclusion criteria [26]. Together these tri-
als suggest that using this serum ferritin threshold of <15
ng/ml is reasonable in NAID, but for higher serum fer-
ritin levels evidence is clearly lacking. Moreover, it has
to be pointed out that OIS is similarly effective in fatigue
in NAID, as two randomised controlled trials showed [28,
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29]. In our study, we found that patients receiving OIS had
more often NAID and serum ferritin above 15 ng/ml than
patients receiving IVIS; however, potential overuse of OIS
may be less relevant because of lower concerns about treat-
ment risks and lower direct costs compared with IVIS.
Variability in healthcare and heterogeneity of recom-
mendations
Patient factors associated with prescribing IVIS instead of
OIS were the severity of iron deficiency and the presence
of comorbid CKD and IBD. To consider CKD and IBD as
a reason to favour IVIS is clearly supported by other evi-
dence [12, 30]. The severity of iron deficiency itself, how-
ever, is not commonly specified by guidelines as a reason
to forgo OIS and directly initiate IVIS. Swiss GPs may,
however, follow the recommendations of the Health Tech-
nology Assessment published by the Swiss Medical Board
in 2014, which explicitly recommends IVIS in severe iron
deficiency because of faster restoration of iron stores and
assumed superiority in quality-adjusted life years [31]. An-
Figure 1: Study design and inclusion/exclusion criteria including numbers of patients and cases. GP = general practitioner; OIS = oral iron
supplementation; IVIS = intravenous iron supplementation; S-ferritin = serum ferritin; CHF = chronic heart failure; RLS = restless legs syn-
drome; CKD = chronic kidney disease stage 3b or higher
Original article Swiss Med Wkly. 2019;149:w20127
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 4 of 9
other reason for choosing IVIS over OIS might be side
effects previously experienced under OIS, which are ex-
pected to occur in 4 to 47% of cases, depending on the
preparation [32]. In our study, we registered a previous at-
tempt at treatment with OIS in one out of five IVIS cases.
GP-related factors associated with prescribing IVIS in-
stead of OIS were sex and practice. The latter is not sur-
prising, given that GPs working together in a practice share
not only infrastructure but also are likely to follow similar
guidelines and processes of care. The finding that male
GPs were more likely than female GPs to prescribe IVIS
suggests that gender-related factors contribute to treatment
decisions. Such a provider-dependency in healthcare ser-
vices, however, may be problematic because arguably in-
dications primarily rest on patient factors.
In the literature there is substantial heterogeneity in the
definition of iron deficiency, which may contribute to the
heterogeneity of medical practice. An illustrative example
for published but divergent expert opinions is Lopez et al.,
who recommended a serum ferritin threshold for iron defi-
ciency of <15 ng/ml in The Lancet in 2016 and Camaschel-
la, who recommended <30 ng/ml in The New England
Journal of Medicine in 2015 [3, 24]. The implications of
defining such margins for categorising a disease is shown
by Schleiffenbaum et al., who determined that a surprising
7% of Swiss army draftees are iron deficient using a
threshold of 30 ng/ml, or by Schueppbach et al. who found
that 50% of healthy female Swiss hospital employees have
serum ferritin below 22 ng/ml [33, 34].
Strengths and limitations
A major strength of this study is that it more precisely
defines the setting where potential overuse of IVIS in
Switzerland occurs. Thereby the study follows up on previ-
ous research that discovered a dramatic increase in IVIS in
Switzerland over the last decade. A second major strength
is the reach of the FIRE database, which covers 8% of GPs
from the German-speaking area of Switzerland and their
accrued real-life routine clinical data. However, GPs par-
ticipating in the FIRE network might not be completely
representative, as EMR users are younger and more often
work in group practices [35]. Since GP age was not asso-
ciated with our outcomes, we expect no relevant bias from
this factor.
An important limitation of this study is information miss-
ing from EMR. Missing laboratory data (haemoglobin and
ferritin) especially led to exclusion of a significant pro-
portion of cases, which may convey a risk of selection
bias. However, the proportion of cases excluded because
of missing laboratory data did not differ between OIS and
IVIS, which argues against an association with the main
outcomes of our study. Interestingly, Giger et al. found
very similar proportions of missing laboratory data in pa-
tients on iron supplementation [15]. This points to the pos-
sibility that physicians actually abstain from complete pre-
treatment testing. Nonetheless, technical reasons may also
have contributed to missing laboratory data in the data-
base. Patient histories preceding coverage in the FIRE pro-
ject may have contained OIS that we missed in our study
and therefore our rate of OIS attempts before IVIS is most
likely an underestimation. Another risk of underestimation
Table 1: Description of cases (total n = 4285).
Variable Intravenous iron
n = 1282
Oral iron
n = 3003
p-value
Median, mean
or n
IQR
(SD) or %
Median, mean
or n
IQR,
(SD) or %
Age at iron supplementation (years) 44 32–66 40 26–53 <0.001*
Sex (female) 1111 86.7% 2662 88.6% 0.0668†
Body mass index (kg/m2) 26.5 (6.5) 25.7 (5.8) 0.051‡
Haemoglobin <3months pretreatment (g/dl) 12.2 (1.7) 12.8 (1.4) <0.001‡
Serum ferritin <3months pretreatment (ng/ml) 17 10–27 23 14–34 <0.001*
Inflammatory bowel disease 134 10.4% 244 8.1% 0.0139‡
Chronic kidney disease stage 3b or higher 65 5.1% 54 1.8% <0.001*
Chronic heart failure 12 0.9% 17 0.6% 0.1762*
Restless legs syndrome 0 0% 4 0.1% 0.3241§
* Wilcoxon rank sum test ; † Chi-square test; ‡ Welch two sample t-test; § Fisher’s exact test
Figure 2: Odds ratios and 95% confidence intervals of variables’ associations with prescribing IVIS instead of OIS, n = 3484. OIS = oral iron
supplementation; IVIS = intravenous iron supplementation; S-ferritin = serum ferritin; GP = general practitioners
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in our study concerns the recognition of comorbidities. Es-
pecially for CHF and RLS, we depended entirely on ac-
curate ICPC coding, which might have been foregone in
some cases by GPs. These comorbidities, however, are rare
in the young population we identified and false negatives
would hardly affect the main findings of our study. Ulti-
mately, to interpret the study outcomes, it is important to
understand that cases of iron supplementation were includ-
ed only once at the initiation of the first treatment cycle in
the database. Thus, the study outcomes represent situations
at the start of iron supplementation, not recurrent treatment
cycles and therefore not the entirety of iron supplementa-
tions.
Implications for further research
From a health-service research perspective, the evidence-
performance gap reflected in overprescription of IVIS in
patients with NAID needs to be better understood. The
next steps in research of medical overuse should explore
how clinical uncertainty and cognitive biases may lead to
overuse [36]. Among possible drivers for overuse of IVIS
are patient expectations, lack of knowledge, heterogene-
ity in the literature, financial incentives or cognitive bias-
es from marketing campaigns deployed by pharmaceutical
companies [37, 38].
Conclusion
When preferring IVIS to OIS, Swiss GPs seem to consider
severity of iron deficiency and comorbid conditions. How-
ever, GPs use iron supplementation mostly in NAID and in
most cases serum ferritin levels are above 15 ng/ml. Over
the last decade, pretreatment serum ferritin levels in IVIS
for NAID have increased, suggesting an ongoing indica-
tion extension and potential overuse.
Data sharing statement
The data are gathered within the ongoing FIRE project.
Additional data that are regularly gathered are stored in the
FIRE database. The FIRE database can be accessed at any
Figure 3: Pretreatment serum ferritin in patients with non-anaemic iron deficiency treated with OIS (red) and IVIS (blue). Curves are fitted with
a least squares regression in localised subsets. OIS = oral iron supplementation; IVIS = intravenous iron supplementation; S-ferritin = serum
ferritin
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time by the scientific team of the institute. For external re-
quests, access has to be requested from the head of the in-
stitute.
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Appendix 1 Supplementary figure
Figure S1: Log odds ratios and 95% confidence intervals of practices and GPs nested in practices for prescription of IVIS instead of OIS. OIS
= oral iron supplementation; IVIS = intravenous iron supplementation; GP = general practitioners; OR = odds ratio
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